Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
It happened. The FDA approved Revolution Medicines’ daraxonrasib for second line pancreatic ductal adenocarcinoma under the CNPV program on July 8. The review took under
Seven weeks ago, retatrutide delivered 28.3% weight loss in TRIUMPH 1—the most effective weight loss data ever produced in a Phase 3 trial. This morning,
KRAS was called undruggable for forty years, and this week it took another beating. Genentech’s divarasib showed superiority over approved therapy in a Phase 3
The GLP 1 story keeps widening, and MASH is the frontier that matters most right now. Novo Nordisk won conditional UK approval for Wegovy in
Back on June 3, when Pfizer and Lilly both signed China deals on the same day, we wrote that the political rhetoric said decouple while
The Tavneos story keeps getting worse, and it now raises a question that should concern every company with a marketed drug: how quickly can a
The obesity market grew up today. When the Medicare GLP 1 Bridge goes live, it marks the shift from the era of scarcity to the
The M&A wave is no longer just a big pharma story. Monday brought two more deals, but neither came from the usual mega cap buyers.
Replimune’s RP1 received two complete response letters from the FDA. Two rejections. Most companies would have shelved the program and moved on. Instead, Replimune resubmitted,
If you work in a pharma or biotech lab, you have used Bio Techne products. The recombinant proteins that populate your assay panels. The antibodies
